Remarkable Response to Erdafitinib in Metastatic Lung Adenocarcinoma With FGFR Fusion
Authors:
- 1 November 2020
- journal article
- research article
- Published by American Society of Clinical Oncology (ASCO) in JCO Precision Oncology
- Vol. 4 (4) , 823-824
Abstract
No abstract availableThis publication has 10 references indexed in Scilit:
- Erdafitinib in Locally Advanced or Metastatic Urothelial CarcinomaNew England Journal of Medicine, 2019
- Phase II study of the FGFR inhibitor AZD4547 in previously treated patients with FGF pathway-activated stage IV squamous cell lung cancer (SqNSCLC): LUNG-MAP sub-study SWOG S1400D.Journal of Clinical Oncology, 2017
- Safety and activity of the pan-fibroblast growth factor receptor (FGFR) inhibitor erdafitinib in phase 1 study patients (Pts) with molecularly selected advanced cholangiocarcinoma (CCA).Journal of Clinical Oncology, 2017
- The FGFR Landscape in Cancer: Analysis of 4,853 Tumors by Next-Generation SequencingClinical Cancer Research, 2016
- Targeting FGFR Signaling in CancerClinical Cancer Research, 2015
- Comprehensive molecular characterization of urothelial bladder carcinomaNature, 2014
- Fibroblast growth factor receptor 2 tyrosine kinase fusions define a unique molecular subtype of cholangiocarcinomaHepatology, 2013
- Identification of Targetable FGFR Gene Fusions in Diverse CancersCancer Discovery, 2013
- Fibroblast growth factor signalling: from development to cancerNature Reviews Cancer, 2010
- The Role of Fibroblast Growth Factors in Tumor GrowthCurrent Cancer Drug Targets, 2009